Cell & Gene Exchange, May 2017: Fibrocell Science, Inc.

June 16, 2017
Fibrocell Science, Inc. (NASDAQ: FCSC) is an autologous cell and gene therapy company translating personalized biologics into medical breakthroughs for diseases affecting the skin and connective tissue. Fibrocell’s most advanced product candidate, FCX-007, has begun a Phase I/II trial for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). Fibrocell is in pre-clinical development of FCX-013, its product candidate for the treatment of linear scleroderma. In addition, Fibrocell has a third program in the research phase for the treatment of arthritis and related conditions. Fibrocell’s gene therapy portfolio is being developed in collaboration with Intrexon Corporation (NYSE: XON), a leader in synthetic biology. For more information, visit http://www.fibrocell.com or follow us on Twitter at @Fibrocell, and LinkedIn. Speaker: John Maslowski – CEO
Previous Video
Cell & Gene Exchange, May 2017: Cellular Dynamics International, Inc.
Cell & Gene Exchange, May 2017: Cellular Dynamics International, Inc.

Cellular Dynamics International (CDI), a FUJIFILM company, is the leading developer and manufacturer of iPS...

Next Video
Cell & Gene Exchange, May 2017: ORIG3N
Cell & Gene Exchange, May 2017: ORIG3N

ORIG3N exists at the intersection of biological science and emerging technology. Our research team uses cut...